Background×COVID-19 (CoranaVirus disease 2019) is an ongoing infectious disease caused by the RNA SARS-CoV-2 virus (Severe Acute Respiratory Syndrome CoronaVirus-2). More than one-third of COVID-19 patients report neurological symptoms and cases of neurological diseases are increasingly accumulating . The aim of this systematic review was to characterize all - to date - reported cases with COVID-19 related myelopathy . Methods×Eighteen papers were included in this review . Patients of all ages could be affected, although there is a predilection for middle-aged people . Results×There were no significant co-morbidities or immunodeficiencies in the affected patients . COVID-19 related myelopathy started roughly within the first month after COVID-19 onset, either concomitantly with COVID-19 symptoms or within 10 days after their remission . The vast majority of cases fulfilled our criteria for postinfectious transverse myelitis . However, some cases were considered to have had parainfectious or infectious myelitis or, in one case, vascular myelopathy . Motor, sensory and bowel and/or bladder symptoms predominated the clinical presentation of myelopathies, explained mainly by centrally localized and longitudinally extensive lesions within the cervical and/or thoracic segments of the spinal cord . Occasionally lesions were complicated by necrosis and hemorrhages . Treatment with corticosteroids, intravenous immunoglobulin or plasma exchange was offered mostly a mild to marked improvement within a period of some weeks . Conclusions× Considering the imminent arrival of new vaccines against COVID-19 pandemic, and their potential risk for postvaccination transverse myelitis, this characterization of COVID-19 related myelopathy is of utmost importance.